Abstract
Prior to the past decade, systemic therapy options for muscle-invasive bladder cancer
(MIBC) or locally advanced/metastatic urothelial carcinoma (la/mUC) were dismal for
cisplatin-ineligible patients and after progression on chemotherapy. Although the
bulk of available evidence for novel systemic therapies exists in the la/mUC setting,
emerging data suggests an important role in the neoadjuvant and adjuvant spaces as
well. In this narrative review, we examine the application of contemporary systemic
therapies to urothelial carcinoma (UC) including immune checkpoint inhibitors (ICIs),
antibody-drug conjugates (ADCs), and targeted therapies. We additionally acknowledge
the potential of combination therapies to further potentiate a durable synergistic
response.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer Statistics, 2021.CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
Flaig TW, Spiess PE, Chair V, et al. NCCN Guidelines Version 2.2022 Bladder Cancer.; 2022. https://www.nccn.org/home/member-
- Treatment of patients with metastatic urothelial cancer “Unfit” for cisplatin-based chemotherapy.Journal of Clinical Oncology. 2011; 29: 2432-2438https://doi.org/10.1200/JCO.2011.34.8433
- Mechanisms of resistance to immune checkpoint inhibitors.Br J Cancer. 2018; 118: 9-16https://doi.org/10.1038/bjc.2017.434
- CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition.American Journal of Clinical Oncology: Cancer Clinical Trials. 2016; 39: 98-106https://doi.org/10.1097/COC.0000000000000239
- Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data.Eur Urol. 2005; 48: 202-206https://doi.org/10.1016/j.eururo.2005.04.006
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med. 2003; 349: 859-866https://doi.org/10.1056/NEJMoa022148
- Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study.Journal of Clinical Oncology. 2018; 36: 3353-3360https://doi.org/10.1200/JCO.18.01148
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.Eur Urol. 2020; 77: 439-446https://doi.org/10.1016/j.eururo.2019.10.026
- Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.Future Oncology. 2021; 17: 3137-3150https://doi.org/10.2217/fon-2021-0273
- Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial.Clinical Cancer Research. 2010; 16: 2861-2871https://doi.org/10.1158/1078-0432.CCR-10-0569
- Phase Ib/II Neoadjuvant (N-) Pembrolizumab (P) and Chemotherapy for Locally Advanced Urothelial Cancer (laUC): Final Results from the Cisplatin (C)-eligible Cohort of HCRN GU14-188.J Clin Oncol. 2020; 38 (5047-5047)
- Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.Journal of Clinical Oncology. 2020; 38 (439-439)https://doi.org/10.1200/JCO.2020.38.6_suppl.439
- Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.Journal of Clinical Oncology. 2022; 40 (528-528)https://doi.org/10.1200/JCO.2022.40.6_suppl.528
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.Eur Urol. August 1, 2022; (Published online)https://doi.org/10.1016/j.eururo.2022.04.013
- Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: A study protocol for an open-label, two-cohort, phase II trial.BMJ Open. 2020; 10https://doi.org/10.1136/bmjopen-2019-035530
- Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).Journal of Clinical Oncology. 2021; 39 (e16510-e16510)https://doi.org/10.1200/JCO.2021.39.15_suppl.e16510
- A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).Journal of Clinical Oncology. 2021; 39 (TPS505-TPS505)https://doi.org/10.1200/JCO.2021.39.6_suppl.TPS505
- Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).BMC Cancer. 2021; 21https://doi.org/10.1186/s12885-021-08990-3
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.Nat Med. 2020; 26: 1839-1844https://doi.org/10.1038/s41591-020-1085-z
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.Nat Med. 2020; 26: 1845-1851https://doi.org/10.1038/s41591-020-1086-y
- Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.Bull Cancer. 2020; 107: eS8-eS15https://doi.org/10.1016/S0007-4551(20)30281-2
- ENERGIZE: A Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.Future Oncology. 2019; 16: 4359-4368https://doi.org/10.2217/fon-2019-0611
- Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).Journal of Clinical Oncology. 2021; 39 (4531-4531)https://doi.org/10.1200/JCO.2021.39.15_suppl.4531
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.New England Journal of Medicine. 2021; 384: 2102-2114https://doi.org/10.1056/nejmoa2034442
U.S. Food & Drug Administration. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. FDA News Release. Published August 19, 2021. Accessed August 18, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma#:∼:text=FDA%20approves%20nivolumab%20for%20adjuvant%20treatment%20of%20urothelial%20carcinoma,-Share&text=On%20August%2019%2C%202021%2C%20the,recurrence%20after%20undergoing%20radical%20resection.
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2021; 22: 525-537https://doi.org/10.1016/S1470-2045(21)00004-8
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.Nature. 2021; 595: 432-437https://doi.org/10.1038/s41586-021-03642-9
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR).ClinicalTrials.gov Identifier:NCT03244384. 2017; (Published onlineAccessed August 18, 2022)
U.S. Food & Drug Administration. Nivolumab for Treatment of Urothelial Carcinoma. Published February 2, 2017. Accessed September 18, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-treatment-urothelial-carcinoma
Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma. FDA.
- FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer.Genentech. April 17, 2017; (PublishedAccessed August 18, 2022)
Galsky MD, Ángel J, Arija A, et al. Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. Vol 395.; 2020. www.thelancet.com
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol. 2020; 21: 1574-1588https://doi.org/10.1016/S1470-2045(20)30541-6
- Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.Cancer Treat Rev. 2022; 104102360https://doi.org/10.1016/j.ctrv.2022.102360
Balar A v., Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67-76. doi:10.1016/S0140-6736(16)32455-2
- FDA approves new, targeted treatment for bladder cancer.FDA News Release. May 16, 2016; (PublishedAccessed August 18, 2022)
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial.The Lancet. 2016; 387: 1909-1920https://doi.org/10.1016/S0140-6736(16)00561-4
- Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study.Annals of Oncology. 2017; 28: 3044-3050https://doi.org/10.1093/annonc/mdx518
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.The Lancet. 2018; 391: 748-757https://doi.org/10.1016/S0140-6736(17)33297-X
- Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.Eur Urol. 2021; 80: 7-11https://doi.org/10.1016/j.eururo.2021.03.024
- Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab.Clinical Cancer Research. 2020; 26: 5487-5493https://doi.org/10.1158/1078-0432.CCR-20-1876
- Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.Eur Urol. 2020; 78: 540-543https://doi.org/10.1016/j.eururo.2020.06.061
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2017; 18: 1483-1492https://doi.org/10.1016/S1470-2045(17)30616-2
Vuky J, Balar Av, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Vol 38.; 2020. https://doi.org/10.
- Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.Eur Urol Oncol. 2020; 3: 351-359https://doi.org/10.1016/j.euo.2020.02.009
- Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.J Urol. 2021; 206: 240-251https://doi.org/10.1097/JU.0000000000001768
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 931-945https://doi.org/10.1016/S1470-2045(21)00152-2
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.New England Journal of Medicine. 2017; 376: 1015-1026https://doi.org/10.1056/nejmoa1613683
- Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.Clin Genitourin Cancer. 2022; (Published online)https://doi.org/10.1016/j.clgc.2022.05.001
Article info
Publication history
Accepted:
January 8,
2023
Received:
November 16,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
Submission to “Review Article” section (invited narrative review): submission with minor revisions
Author Disclosures: UroGen Pharma (Scientific Advisory Board, Consultant, and Speaker Bureau); BMS (Scientific Advisory Board, Research Funding, and Speaker Bureau); and ImmunityBio (Scientific Advisory Board and Consultant)
Research Funding: None
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
